# CareDx Reports 39% Revenue Growth as Testing Volume Climbs 51%

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/55085
Published: 2026-11-12T07:29:58.000Z
Updated: 2026-11-12T07:29:58.000Z
Section: Business

> The diagnostics company recorded $139 million in third-quarter revenue and about 75,900 testing-services procedures.

CareDx recorded $139 million in third-quarter 2026 revenue, a 39% increase from a year earlier. Testing-services volume rose 51% to about 75,900 for the quarter ended Sept. 30.

The company focuses on diagnostics for transplant, specialty oncology and cell therapy. Its testing services include NavDx, a blood-based test used to detect and monitor certain HPV-associated cancers.

CareDx completed its acquisition of Naveris on July 1, 2026. The deal added NavDx to the company’s portfolio.